Haiqiang Dou

Dr. Haiqiang Dou

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Physiological Reports
Verified
Journal Article
Open access
PDF file
RRReshma Ramracheya
Reshma Ramracheya
CCCaroline Chapman
Caroline Chapman
MCMargarita Chibalina
Margarita Chibalina
Haiqiang DouHaiqiang Dou
Haiqiang Dou
CMCaroline Miranda
Caroline Miranda
LBLinford J. B. Briant
Linford J. B. Briant
Glucagon is the body's main hyperglycemic hormone, and its secretion is dysregulated in type 2 diabetes mellitus (T2DM). The incretin hormone glucagon‐like peptide‐1 (GLP‐1) is released from the gut and is used in T2DM therapy. Uniquely, it both stimulates insulin and inhibits glucagon secretion and thereby lowers plasma glucose levels. In this study, we have investigated the action of GLP‐1 on glucagon release from human pancreatic islets. Immunocytochemistry revealed that only <0.5% of the α‐cells possess detectable GLP‐1R immunoreactivity. Despite this, GLP‐1 inhibited glucagon secretion by 50–70%. This was due to a direct effect on α‐cells, rather than paracrine signaling, because the inhibition was not reversed by the insulin receptor antagonist S961 or the somatostatin receptor‐2 antagonist CYN154806. The inhibitory effect of GLP‐1 on glucagon secretion was prevented by the PKA‐inhibitor Rp‐cAMPS and mimicked by the adenylate cyclase activator forskolin. Electrophysiological measurements revealed that GLP‐1 decreased action potential height and depolarized interspike membrane potential. Mathematical modeling suggests both effects could result from inhibition of P/Q‐type Ca2+ channels. In agreement with this, GLP‐1 and ω‐agatoxin (a blocker of P/Q‐type channels) inhibited glucagon secretion in islets depolarized by 70 mmol/L [K+]o, and these effects were not additive. Intracellular application of cAMP inhibited depolarization‐evoked exocytosis in individual α‐cells by a PKA‐dependent (Rp‐cAMPS‐sensitive) mechanism. We propose that inhibition of glucagon secretion by GLP‐1 involves activation of the few GLP‐1 receptors present in the α‐cell membrane. The resulting small elevation of cAMP leads to PKA‐dependent inhibition of P/Q‐type Ca2+ channels and suppression of glucagon exocytosis.

1 December 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
OOOkechi S. Oduori
Okechi S. Oduori
NMNaoya Murao
Naoya Murao
KSKenju Shimomura
Kenju Shimomura
HTHarumi Takahashi
Harumi Takahashi
QZQuan Zhang
Quan Zhang
SSSusumu Seino
Susumu Seino
By restoring glucose-regulated insulin secretion, glucagon-like peptide-1–based (GLP-1–based) therapies are becoming increasingly important in diabetes care. Normally, the incretins GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) jointly maintain normal blood glucose levels by stimulation of insulin secretion in pancreatic β cells. However, the reason why only GLP-1–based drugs are effective in improving insulin secretion after presentation of diabetes has not been resolved. ATP-sensitive K+ (KATP) channels play a crucial role in coupling the systemic metabolic status to β cell electrical activity for insulin secretion. Here, we have shown that persistent membrane depolarization of β cells due to genetic (β cell–specific Kcnj11–/– mice) or pharmacological (long-term exposure to sulfonylureas) inhibition of the KATP channel led to a switch from Gs to Gq in a major amplifying pathway of insulin secretion. The switch determined the relative insulinotropic effectiveness of GLP-1 and GIP, as GLP-1 can activate both Gq and Gs, while GIP only activates Gs. The findings were corroborated in other models of persistent depolarization: a spontaneous diabetic KK-Ay mouse and nondiabetic human and mouse β cells of pancreatic islets chronically treated with high glucose. Thus, a Gs/Gq signaling switch in β cells exposed to chronic hyperglycemia underlies the differential insulinotropic potential of incretins in diabetes.

7 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
QPQuinn P Peterson
Quinn P Peterson
AVAdrian Veres
Adrian Veres
LCLihua Chen
Lihua Chen
MSMichael Q. Slama
Michael Q. Slama
JKJennifer H. R. Kenty
Jennifer H. R. Kenty
DMDouglas A. Melton
Douglas A. Melton
The generation of pancreatic cell types from renewable cell sources holds promise for cell replacement therapies for diabetes. Although most effort has focused on generating pancreatic beta cells, considerable evidence indicates that glucagon secreting alpha cells are critically involved in disease progression and proper glucose control. Here we report on the generation of stem cell-derived human pancreatic alpha (SC-alpha) cells from pluripotent stem cells via a transient pre-alpha cell intermediate. These pre-alpha cells exhibit a transcriptional profile similar to mature alpha cells and although they produce proinsulin protein, they do not secrete significant amounts of processed insulin. Compound screening identified a protein kinase c activator that promotes maturation of pre-alpha cells into SC-alpha cells. The resulting SC-alpha cells do not express insulin, share an ultrastructure similar to cadaveric alpha cells, express and secrete glucagon in response to glucose and some glucagon secretagogues, and elevate blood glucose upon transplantation in mice.

22 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYingying Ye
Yingying Ye
MBMohammad Barghouth
Mohammad Barghouth
Haiqiang DouHaiqiang Dou
Haiqiang Dou
CLCheng Luan
Cheng Luan
YWYongzhi Wang
Yongzhi Wang
ERErik Renström
Erik Renström
Glucose-induced insulin secretion depends on β-cell electrical activity. Inhibition of ATP-regulated potassium (KATP) channels is a key event in this process. However, KATP channel closure alone is not sufficient to induce β-cell electrical activity; activation of a depolarizing membrane current is also required. Here we examine the role of the mechanosensor ion channel PIEZO1 in this process. Yoda1, a specific PIEZO1 agonist, activates a small membrane current and thereby triggers β-cell electrical activity with resultant stimulation of Ca2+-influx and insulin secretion. Conversely, the PIEZO1 antagonist GsMTx4 reduces glucose-induced Ca2+-signaling, electrical activity and insulin secretion. Yet, PIEZO1 expression is elevated in islets from human donors with type-2 diabetes (T2D) and a rodent T2D model (db/db mouse), in which insulin secretion is reduced. This paradox is resolved by our finding that PIEZO1 translocates from the plasmalemma into the nucleus (where it cannot influence the membrane potential of the β-cell) under experimental conditions emulating T2D (high glucose culture). β-cell-specific Piezo1-knockout mice show impaired glucose tolerance in vivo and reduced glucose-induced insulin secretion, β-cell electrical activity and Ca2+ elevation in vitro. These results implicate mechanotransduction and activation of PIEZO1, via intracellular accumulation of glucose metabolites, as an important physiological regulator of insulin secretion.

21 May 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
SSShujiang Shang
Shujiang Shang
XKXinjiang Kang
Xinjiang Kang
STSasa Teng
Sasa Teng
FZFeipeng Zhu
Feipeng Zhu
ZZZhuan Zhou
Zhuan Zhou
Striatal dopamine (DA) release can be independently triggered not only by action potentials (APs) in dopaminergic axons but also APs in cholinergic interneurons (ChIs). Nicotine causes addiction by modulating DA release, but with paradoxical findings. Here, we investigate how physiologically relevant levels of nicotine modulate striatal DA release. The optogenetic stimulation of ChIs elicits DA release, which is potently inhibited by nicotine with an IC50 of 28 nM in the dorsal striatum slice. This ChI-driven DA release is predominantly mediated by α6β2* nAChRs. Local electrical stimulus (Estim) activates both dopaminergic axons and ChIs. Nicotine does not affect the APDA-dependent DA release (APDA, AP of dopaminergic axon). During burst Estim, nicotine permits the facilitation of DA release by prevention of DA depletion. Our work indicates that cholinergic stimulation-induced DA release is profoundly modulated by physiologically relevant levels of nicotine and resolves the paradoxical observation of nicotine’s effects on striatal DA release.

19 December 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
Amir HatamieAmir Hatamie
Amir Hatamie
LRLin Ren
Lin Ren
Haiqiang DouHaiqiang Dou
Haiqiang Dou
Nikhil GandasiNikhil Gandasi
Nikhil Gandasi
PRPatrik Rorsman
Patrik Rorsman
Andrew G. EwingAndrew G. Ewing
Andrew G. Ewing
Recent work has shown that chemical release during the fundamental cellular process of exocytosis in model cell lines is not all‐or‐none. We tested this theory for vesicular release from single pancreatic beta cells. The vesicles in these cells release insulin, but also serotonin, which is detectible with amperometric methods. Traditionally, it is assumed that exocytosis in beta cells is all‐or‐none. Here, we use a multidisciplinary approach involving nanoscale amperometric chemical methods to explore the chemical nature of insulin exocytosis. We amperometrically quantified the number of serotonin molecules stored inside of individual nanoscale vesicles (39 317±1611) in the cell cytoplasm before exocytosis and the number of serotonin molecules released from single cells (13 310±1127) for each stimulated exocytosis event. Thus, beta cells release only one‐third of their granule content, clearly supporting partial release in this system. We discuss these observations in the context of type‐2 diabetes.